Cure8 trial brief
A new Phase 2 study is testing an investigational injectable drug (called “627”) for moderate to severe ulcerative colitis. People with UC who have not responded to or cannot tolerate current therapies are the intended population, so the trial could be relevant to those seeking new treatment options.
Adults with moderate–severe UC, patients with inadequate response or intolerance to current UC therapies, clinicians treating UC, and researchers following drug development for IBD.
This is a Phase 2 interventional clinical trial (NCT07507513) testing an investigational injectable drug referred to as “627” versus placebo in adults with moderate to severe ulcerative colitis (UC). The study is recruiting and plans to enroll about 288 participants across multiple dose groups, with safety (adverse events) tracked through a 36‑week period.
The trial enrolls adults (18–75) with at least 3 months of UC and who have moderate–severe active disease and prior inadequate response, loss of response, intolerance to one or more therapies, or corticosteroid dependence. It uses subcutaneous injections of 627 at several dose levels and includes a placebo arm.
The record lists standard eligibility and exclusion criteria (e.g., infection screening, recent major surgery, malignancy history, vaccine restrictions, contraception requirements). Locations include a site in Guangzhou, China. This entry is a trial registry record describing planned study design and not trial results.
No efficacy or safety results are reported in this registry entry; it describes the study protocol, arms, and primary safety outcome (adverse events) only.
This is a clinicaltrials.gov registry record describing a planned Phase 2 trial (protocol-level information). The record does not include study results; it documents design, eligibility, interventions, and planned safety outcome. As with any registered trial, enrollment, conduct, and results may change over time.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...
This trial tests two investigational agents (eltrekibart and mirikizumab) for moderate–severe ulcerative colitis, which may offer additional treatment options if proven safe and effective. It’s relevant to people whose...
This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...
